(Corrects dateline to August 26) (Reuters) -Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

Eli Lilly said its once-daily weight loss pill was effective for people with obesity and type 2 diabetes in a key trial, clearing the way for the drugmaker to seek regulatory approval across the globe.